§ 50.54 Clinical investigations not otherwise approvable that present an opportunity to understand, prevent, or alleviate a serious problem affecting the health or welfare of children.

If an IRB does not believe that a clinical investigation within the scope described in §§ 50.1 and 56.101 of this chapter and involving children as subjects meets the requirements of §50.51, §50.52, or §50.53, the clinical investigation may proceed only if:

- (a) The IRB finds and documents that the clinical investigation presents a reasonable opportunity to further the understanding, prevention, or alleviation of a serious problem affecting the health or welfare of children; and
- (b) The Commissioner of Food and Drugs, after consultation with a panel of experts in pertinent disciplines (for example: science, medicine, education, ethics, law) and following opportunity for public review and comment, determines either:
- (1) That the clinical investigation in fact satisfies the conditions of §50.51, §50.52, or §50.53, as applicable, or
- (2) That the following conditions are met:
- (i) The clinical investigation presents a reasonable opportunity to further the understanding, prevention, or alleviation of a serious problem affecting the health or welfare of children;
- (ii) The clinical investigation will be conducted in accordance with sound ethical principles; and
- (iii) Adequate provisions are made for soliciting the assent of children and the permission of their parents or guardians as set forth in §50.55.

## § 50.55 Requirements for permission by parents or guardians and for assent by children.

- (a) In addition to the determinations required under other applicable sections of this subpart D, the IRB must determine that adequate provisions are made for soliciting the assent of the children when in the judgment of the IRB the children are capable of providing assent.
- (b) In determining whether children are capable of providing assent, the IRB must take into account the ages, maturity, and psychological state of

the children involved. This judgment may be made for all children to be involved in clinical investigations under a particular protocol, or for each child, as the IRB deems appropriate.

- (c) The assent of the children is not a necessary condition for proceeding with the clinical investigation if the IRB determines:
- (1) That the capability of some or all of the children is so limited that they cannot reasonably be consulted, or
- (2) That the intervention or procedure involved in the clinical investigation holds out a prospect of direct benefit that is important to the health or well-being of the children and is available only in the context of the clinical investigation.
- (d) Even where the IRB determines that the subjects are capable of assenting, the IRB may still waive the assent requirement if it finds and documents that:
- (1) The clinical investigation involves no more than minimal risk to the subjects;
- (2) The waiver will not adversely affect the rights and welfare of the subjects:
- (3) The clinical investigation could not practicably be carried out without the waiver; and
- (4) Whenever appropriate, the subjects will be provided with additional pertinent information after participation.
- (e) In addition to the determinations required under other applicable sections of this subpart D, the IRB must determine that the permission of each child's parents or guardian is granted.
- (1) Where parental permission is to be obtained, the IRB may find that the permission of one parent is sufficient, if consistent with State law, for clinical investigations to be conducted under §50.51 or §50.52.
- (2) Where clinical investigations are covered by \$50.53 or \$50.54 and permission is to be obtained from parents, both parents must give their permission unless one parent is deceased, unknown, incompetent, or not reasonably available, or when only one parent has legal responsibility for the care and custody of the child if consistent with State law.